

Content Overview

Preamble	VII
Table of contents	XI
List of tables	XVII
Introduction	1
Part 1 New ways to define personalised medicine	9
Chapter 1 Definitions and terminology in personalised medicine	10
Chapter 2 Classification of personalised medicine: precision medicine and individualised medicine	17
Part 2 Diagnostic testing in personalised medicine	31
Chapter 3 Definition and impact of diagnostic testing	31
Chapter 4 Data collection and analysis	34
Chapter 5 Results of diagnostic methods	43
Part 3 Precision medicine based on a previously known substance or composition	49
Chapter 6 Second medical use claims for identified patients (sub)groups and dosage regimen	51
Chapter 7 Precision medicine as privileged medicine?	56
Part 4 Genuine precision medicine patents	65
Chapter 8 Genuine precision medicine: a rediscovered concept	65
Chapter 9 Initial step: Collection	72
Chapter 10 Preparation stage: Manufacturing products in the era of genuine precision medicine	74
Chapter 11 Application stage: Treating a patient by administering a product of genuine precision medicine	83
Part 5 Individualised medicine	95
Chapter 12 Preface: Individualised medicine – hype or hope?	96
Chapter 13 Patents for methods used in individualised medicine	106
Chapter 14 Validity for product patents in individualised medicine	114

Part 6	Alternative protection tools for inventions in personalised medicine	131
Chapter 15	Trade secrets as an alternative protection tool	132
Chapter 16	Regulatory law	141
	Summary of patent protection for personalised medicine	157
	List of abbreviations and acronyms	163
	Literature	167
	Materials	185
	Case law	189
	Subject Index	193

Table of contents

Preamble	VII
Content Overview	IX
List of tables	XVII
Introduction	1
A. Purpose of the research	2
B. Hypotheses	2
C. State of research	4
I. General literature on personalised medicine	4
II. Literature related to patent law	5
D. Research steps (structure)	5
E. Methods	6
I. Interdisciplinary research method	6
II. Interpretive research method	7
F. Phrasing and relevant terminology	7
Part 1 New ways to define personalised medicine	9
<i>Chapter 1 Definitions and terminology in personalised medicine</i>	10
A. Different categories of medicine	10
I. Conventional medicine	11
II. Regenerative medicine	12
III. Personalised medicine	13
B. Personalised medicine: a working definition	14
I. Personalised medicine vs personalised health and P4 medicine	14
II. A framework for understanding the definition of personalised medicine ..	15
<i>Chapter 2 Classification of personalised medicine: precision medicine and individualised medicine</i>	17
A. Classification	17
B. Medicinal products associated with genuine precision medicine	20
C. Precision medicine based on a previously known substance or composition ..	22
I. Metreleptin	23
II. Fulvestrant	23
D. Individualised medicine	24
I. Individualised anti-cancer vaccines	25
II. iPS cell-based therapies	26
III. Individual data-based medicines	27
E. Working definitions	28

F. Summary	29
Part 2 Diagnostic testing in personalised medicine	31
<i>Chapter 3 Definition and impact of diagnostic testing</i>	<i>31</i>
A. Personalised diagnostics	32
I. Main purpose	33
II. Structure and elements	33
III. Patent protection	34
<i>Chapter 4 Data collection and analysis</i>	<i>34</i>
A. Data collection and data per se	34
I. Non-biological data	35
II. Biological data	35
B. Detecting the presence of a biomarker	36
C. Biomarker and data comparison	38
I. Comparing patient data samples	38
II. Finding significant differences	38
1. The role of biomarkers in dividing patients into groups (stratification)	39
2. Role of AI in data analysis	39
a) AI as a diagnostic tool	40
b) Use of algorithms in personalised diagnostics: Verinata Health, Inc. v. Ariosa Diagnostics, Inc.	41
<i>Chapter 5 Results of diagnostic methods</i>	<i>43</i>
A. Diagnostic method results are not patent eligible	44
B. Can diagnostic method results be patentable subject matter?	44
I. Rezeptortyrosinkinase II	45
II. Rezeptortyrosinkinase II – meaning for personalised medicine	46
C. Interim results	47
Part 3 Precision medicine based on a previously known substance or composition	49
<i>Chapter 6 Second medical use claims for identified patients (sub)groups and dosage regimen</i>	<i>51</i>
A. Second medical use claims: requirements	51
I. Novelty	51
II. Inventive step	53
III. Sufficient disclosure	54
B. The patient (sub)group as a way to avoid irreproducibility	55
<i>Chapter 7 Precision medicine as privileged medicine?</i>	<i>56</i>
A. “Personalised” dosage regimen: Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals	56
B. Vanda decision: “Personalisation” as a new form of generic exclusion	60
C. Summary	63

Part 4	Genuine precision medicine patents	65
<i>Chapter 8</i>	<i>Genuine precision medicine: a rediscovered concept</i>	65
A.	The invention	66
I.	CAR-T cell therapy	66
II.	Patent application examples	67
III.	Additional elements of CAR-T cell therapy	70
B.	Patent-related issues	72
<i>Chapter 9</i>	<i>Initial step: Collection</i>	72
A.	Methods of isolating human materials	72
B.	Single stage or method in and of itself	73
<i>Chapter 10</i>	<i>Preparation stage: Manufacturing products in the era of genuine precision medicine</i>	74
A.	Biological materials as a human body parts	74
I.	Biological material as a patentable subject matter	75
II.	Biological materials patentability in the light of ethical issues	75
1.	Human embryos and embryonic stem cells	76
2.	“Artificial” human embryos	77
B.	Patents on products of genuine precision medicine	78
I.	Products of genuine precision medicine: a characteristic	78
II.	Absolute patent protection	79
III.	Product-by-process claims	80
IV.	Product patents limited to specific use	81
C.	Method patents	82
<i>Chapter 11</i>	<i>Application stage: Treating a patient by administering a product of genuine precision medicine</i>	83
A.	Substances or compositions used in therapy vs methods of treatment involving surgery or therapy practised on the human or animal body	84
B.	Personalised medicine: exclusion from patent protection	86
I.	Patent applications not subject to patentability exclusion	86
II.	Patent applications subject to patentability exclusion	87
III.	The role of healthcare practitioner	89
1.	Health risks connected to the treatment	89
2.	Use of surgical instruments	90
IV.	Personalised medicine: product or therapeutic method?	91
C.	Summary	92
Part 5	Individualised medicine	95
<i>Chapter 12</i>	<i>Preface: Individualised medicine – hype or hope?</i>	96
A.	Precision vs. Individualised medicine	97
B.	Patents on inventions in individualised medicine: examples	98
I.	Peptide-based personalised anti-cancer vaccines	99
1.	General findings	101
2.	Semi-customised approach	102

II. RNA-based individualised medicinal products	102
III. Individualised medicine: a new era for pharmaceutical patents?	104
1. Individualised medicine equals data-based medicine?	104
a) Protection for “patient identity”	105
b) Patents on methods for the identification of unique information	105
2. Protection for an individualised product, process or use?	106
<i>Chapter 13 Patents for methods used in individualised medicine</i>	106
A. Industrial applicability in the case of individualised method patents	107
I. Semi-customised approach	108
1. A method intended to manufacture an individualised medicine is not a therapeutic method	110
2. A method intended to manufacture an individualised medicine is industrially applicable	110
II. Fully-customised approach	111
B. Methods used for the manufacture of individualised medicinal products: sufficient disclosure	112
I. Standardised method of manufacture	112
II. Fully-customised methods of manufacture	113
<i>Chapter 14 Validity for product patents in individualised medicine</i>	114
A. Product unknown prior to the manufacture thereof	114
B. Individualised products as a unique substance or composition	116
I. Individualised products: lack of industrial applicability	116
1. Reproducibility	117
a) Implementation exclusively by the inventor	118
b) Availability of biological material as a constituent of an individualised product	118
2. Usability	119
3. Completeness	121
II. Individualised therapies as industrially applicable therapies	121
1. Prediction is sufficient for industrial applicability: Human Genome Sciences, Inc. v Eli Lilly and Co.	121
2. Individualised products in the light of Human Genome Sciences, Inc. v Eli Lilly and Co.	123
III. Individualised products: lack of sufficient disclosure	123
C. Individualised medicinal products as information carriers	125
I. Genetic information as a unique information carrier	126
II. Product patents on unique information carriers	127
D. Second and further medical use claims for individualised products	128
E. Interim results	129
Part 6 Alternative protection tools for inventions in personalised medicine	131
<i>Chapter 15 Trade secrets as an alternative protection tool</i>	132
A. Trade secrets: the core of company competitiveness	132
I. Trade secrets: definition	133
1. Definition and concept of “trade secrets”	134
2. Trade secrets and transparency rules	134

a) Confidential information in applications for marketing authorisation	135
b) Transparency rules and personalised medicine or the elements thereof	136
II. Trade secrets: protection	137
III. Trade secret law and patent law	138
B. Trade secret and personalised medicine inventions protection	139
C. Conclusions	140
<i>Chapter 16 Regulatory law</i>	141
A. Regulatory law: exclusivities and exemptions mechanisms	142
B. Lack of a common category for personalised medicinal products	143
I. Personalised medicine and companion diagnostics	145
II. Personalised medicines as a small-molecule drugs (substances)	145
III. Personalised medicines as ATMPs	146
1. The Hospital Exemption	146
2. Personalised medicine and the Hospital Exemption: possible but irrelevant?	147
IV. Personalised medicines as orphan drugs	148
1. Orphan medicinal products	148
2. "Orphanization"	149
3. Exclusivity mechanisms	150
V. Individualised medicine: experimental drugs?	151
1. Semi-customised individualised medicinal products	152
2. Fully-customised individualised medicinal products	152
C. Regulatory law: not the ultima ratio for personalised medicine	154
D. Interim results	156
Summary of patent protection for personalised medicine	157
List of abbreviations and acronyms	163
Literature	167
Materials	185
Case law	189
Subject Index	193